Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590

Heather A. Wakelee, Patricia Stephenson, Steven M. Keller, Henry Wagner Jr., Arnold Herskovic, Ritsuko Komaki, Randolph S. Marks, Michael C. Perry, Robert B. Livingston, David H. Johnson

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

To determine the influence of adjuvant therapy on the risk of DID following resection of NSCLC, we compared the actuarial rate of non-cancer related deaths of patients who had been entered in Eastern Cooperative Oncology Group E3590 (a phase III trial of adjuvant therapy in patients with completely resected stages II and IIIA NSCLC) to the actuarial death rate of age and gender matched controls. Following surgery, patients were randomized to receive either PORT (5040 cGy in 28 daily fractions) or CPORT (PORT plus four cycles of cisplatin (60 mg/m2, day 1) and etoposide (120 mg/m2, days 1-3) administered concurrently). The study accrued 488 patients, 242 to the PORT only arm and 246 to the CPORT arm. The overall 4 years actuarial rate of DID for the two arms combined, with a median follow-up of 82 months, was 12.9%, not significantly different from the 10.1% expected rate of DID, based on mortality rates for age and gender matched controls derived from US vital statistics and corrected for smoking status (p = 0.16). Survival distributions with regard to DID did not differ between the two treatment arms (p = 0.96). DID increased with age (treated as a continuous variable, p < 0.01), but was not affected by histology, side of chest irradiated, type of surgery, FEV1 or weight loss in the previous 6 months. The risk of DID following resection of stages II and IIIA NSCLC is not increased in patients who received PORT or CPORT.

Original languageEnglish (US)
Pages (from-to)389-397
Number of pages9
JournalLung Cancer
Volume48
Issue number3
DOIs
StatePublished - Jun 1 2005

Fingerprint

Chemoradiotherapy
Non-Small Cell Lung Carcinoma
Radiotherapy
Arm
Mortality
Vital Statistics
Etoposide
Cisplatin
Weight Loss
Histology
Thorax
Therapeutics
Smoking
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Wakelee, Heather A. ; Stephenson, Patricia ; Keller, Steven M. ; Wagner Jr., Henry ; Herskovic, Arnold ; Komaki, Ritsuko ; Marks, Randolph S. ; Perry, Michael C. ; Livingston, Robert B. ; Johnson, David H. / Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. In: Lung Cancer. 2005 ; Vol. 48, No. 3. pp. 389-397.
@article{d8523747e5024eedb51aa77895ba8d26,
title = "Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590",
abstract = "To determine the influence of adjuvant therapy on the risk of DID following resection of NSCLC, we compared the actuarial rate of non-cancer related deaths of patients who had been entered in Eastern Cooperative Oncology Group E3590 (a phase III trial of adjuvant therapy in patients with completely resected stages II and IIIA NSCLC) to the actuarial death rate of age and gender matched controls. Following surgery, patients were randomized to receive either PORT (5040 cGy in 28 daily fractions) or CPORT (PORT plus four cycles of cisplatin (60 mg/m2, day 1) and etoposide (120 mg/m2, days 1-3) administered concurrently). The study accrued 488 patients, 242 to the PORT only arm and 246 to the CPORT arm. The overall 4 years actuarial rate of DID for the two arms combined, with a median follow-up of 82 months, was 12.9{\%}, not significantly different from the 10.1{\%} expected rate of DID, based on mortality rates for age and gender matched controls derived from US vital statistics and corrected for smoking status (p = 0.16). Survival distributions with regard to DID did not differ between the two treatment arms (p = 0.96). DID increased with age (treated as a continuous variable, p < 0.01), but was not affected by histology, side of chest irradiated, type of surgery, FEV1 or weight loss in the previous 6 months. The risk of DID following resection of stages II and IIIA NSCLC is not increased in patients who received PORT or CPORT.",
author = "Wakelee, {Heather A.} and Patricia Stephenson and Keller, {Steven M.} and {Wagner Jr.}, Henry and Arnold Herskovic and Ritsuko Komaki and Marks, {Randolph S.} and Perry, {Michael C.} and Livingston, {Robert B.} and Johnson, {David H.}",
year = "2005",
month = "6",
day = "1",
doi = "10.1016/j.lungcan.2004.11.007",
language = "English (US)",
volume = "48",
pages = "389--397",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. / Wakelee, Heather A.; Stephenson, Patricia; Keller, Steven M.; Wagner Jr., Henry; Herskovic, Arnold; Komaki, Ritsuko; Marks, Randolph S.; Perry, Michael C.; Livingston, Robert B.; Johnson, David H.

In: Lung Cancer, Vol. 48, No. 3, 01.06.2005, p. 389-397.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590

AU - Wakelee, Heather A.

AU - Stephenson, Patricia

AU - Keller, Steven M.

AU - Wagner Jr., Henry

AU - Herskovic, Arnold

AU - Komaki, Ritsuko

AU - Marks, Randolph S.

AU - Perry, Michael C.

AU - Livingston, Robert B.

AU - Johnson, David H.

PY - 2005/6/1

Y1 - 2005/6/1

N2 - To determine the influence of adjuvant therapy on the risk of DID following resection of NSCLC, we compared the actuarial rate of non-cancer related deaths of patients who had been entered in Eastern Cooperative Oncology Group E3590 (a phase III trial of adjuvant therapy in patients with completely resected stages II and IIIA NSCLC) to the actuarial death rate of age and gender matched controls. Following surgery, patients were randomized to receive either PORT (5040 cGy in 28 daily fractions) or CPORT (PORT plus four cycles of cisplatin (60 mg/m2, day 1) and etoposide (120 mg/m2, days 1-3) administered concurrently). The study accrued 488 patients, 242 to the PORT only arm and 246 to the CPORT arm. The overall 4 years actuarial rate of DID for the two arms combined, with a median follow-up of 82 months, was 12.9%, not significantly different from the 10.1% expected rate of DID, based on mortality rates for age and gender matched controls derived from US vital statistics and corrected for smoking status (p = 0.16). Survival distributions with regard to DID did not differ between the two treatment arms (p = 0.96). DID increased with age (treated as a continuous variable, p < 0.01), but was not affected by histology, side of chest irradiated, type of surgery, FEV1 or weight loss in the previous 6 months. The risk of DID following resection of stages II and IIIA NSCLC is not increased in patients who received PORT or CPORT.

AB - To determine the influence of adjuvant therapy on the risk of DID following resection of NSCLC, we compared the actuarial rate of non-cancer related deaths of patients who had been entered in Eastern Cooperative Oncology Group E3590 (a phase III trial of adjuvant therapy in patients with completely resected stages II and IIIA NSCLC) to the actuarial death rate of age and gender matched controls. Following surgery, patients were randomized to receive either PORT (5040 cGy in 28 daily fractions) or CPORT (PORT plus four cycles of cisplatin (60 mg/m2, day 1) and etoposide (120 mg/m2, days 1-3) administered concurrently). The study accrued 488 patients, 242 to the PORT only arm and 246 to the CPORT arm. The overall 4 years actuarial rate of DID for the two arms combined, with a median follow-up of 82 months, was 12.9%, not significantly different from the 10.1% expected rate of DID, based on mortality rates for age and gender matched controls derived from US vital statistics and corrected for smoking status (p = 0.16). Survival distributions with regard to DID did not differ between the two treatment arms (p = 0.96). DID increased with age (treated as a continuous variable, p < 0.01), but was not affected by histology, side of chest irradiated, type of surgery, FEV1 or weight loss in the previous 6 months. The risk of DID following resection of stages II and IIIA NSCLC is not increased in patients who received PORT or CPORT.

UR - http://www.scopus.com/inward/record.url?scp=21044438602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044438602&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2004.11.007

DO - 10.1016/j.lungcan.2004.11.007

M3 - Article

C2 - 15893008

AN - SCOPUS:21044438602

VL - 48

SP - 389

EP - 397

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -